Transfusion-dependent Anemia
📧 Sign up to get email alerts when something new happens for Transfusion-dependent Anemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-21Clinical Trial Update: Liberal Transfusion Strategy in Elderly Patients [Phase 3]
Phase 3 trial update on liberal transfusion strategy in elderly patients completed.
-
CLINICAL_TRIALS trial_result · 2026-07-07Clinical Trial Update: Liberal Transfusion Strategy in Elderly Patients [Phase 3]
A Phase 3 clinical trial evaluating liberal transfusion strategy in elderly patients has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload [Phase 2]
A Phase 2 study evaluating an improved deferasirox granule formulation for treatment compliance, efficacy, and safety in pediatric patients …
-
CLINICAL_TRIALS other · 2024-07-29Clinical Trial Update: Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA [Phase 4]
This is a Phase 4 clinical trial update comparing rhTPO plus cyclosporine versus cyclosporine alone in transfusion-dependent aplastic anemia…
-
FDA approval · 2023-11-14FDA Approved: DEFERASIROX — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for deferasirox submitted by Sun Pharmaceutical Industries, Inc., approving changes to the product l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2022-07-18Clinical Trial Update: The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study [Phase 4]
Phase 4 real-world study assessing safety and efficacy of luspatercept in Chinese adults with transfusion-dependent thalassemia (beta-thalas…
-
FDA approval · 2021-03-17FDA Approved: DEFERASOROX — Original Application (Novadoz Pharmaceuticals LLC)
The FDA granted approval for the original ANDA application of Deferasorox (deferasirox) by Novadoz Pharmaceuticals LLC as a generic product.…
-
FDA label_change · 2020-07-23FDA Approved: JADENU — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for JADENU (deferasirox) from Novartis, updating the product labeling.
-
FDA approval · 2019-05-24FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Exjade (deferasirox) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2015-03-30FDA Approved: JADENU — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved JADENU (deferasirox) through an Original Application for the treatment of chronic iron overload due to blood transfusions; the …